- 2 days ago
- 7 min read
Key Takeaways |
A patient with refractory, bone-metastatic lymphoma showed all lesions gone on PET/CT roughly one month after a single CAR-T cell infusion at a top-ranked 3A-grade cancer hospital in Shanghai — one of China's leading oncology centers. |
This was a case where standard treatment, salvage chemotherapy, and even newer targeted therapies had already failed — the disease had spread through her entire skeleton, causing pathological fractures and leaving her unable to walk. |
CAR-T was delivered through a structured, multidisciplinary process: T-cell collection in early October, lab expansion and engineering, reinfusion in November, then close inpatient monitoring in a dedicated Phase I clinical trial ward — with no significant adverse reactions reported. |
This is an early result, not a long-term cure claim. The reporting explicitly frames this as a one-month follow-up snapshot; the treating physicians stated the patient requires continued monitoring to confirm durability. |
The hospital is actively expanding CAR-T beyond blood cancers, running related cell-therapy trials with its pancreatic surgery, gynecologic oncology, head and neck surgery, and bone/soft tissue surgery departments — part of the broader push to bring CAR-T to solid tumors. |
Introduction
Refractory lymphoma — disease that keeps progressing despite multiple lines of treatment — is one of the hardest situations in oncology to turn around. When a patient has already gone through frontline therapy, salvage chemotherapy, and newer targeted drugs without lasting control, options narrow fast, and quality of life often deteriorates alongside the disease.
This case, reported in December 2021, is one of the earliest documented uses of CAR-T cell immunotherapy at this particular Shanghai cancer center for a lymphoma patient in this exact situation. It's a useful data point for understanding what CAR-T access at a major Chinese academic cancer center actually looks like in practice — from eligibility through infusion through monitoring — and it adds to our growing library of documented CAR-T success cases in China, alongside cases like the "Beijing Protocol" allogeneic CAR-T breakthrough at a leading hematology institute in Beijing, showing multiple independent 3A-grade Chinese hospitals running their own CAR-T programs with their own clinical infrastructure. For the full landscape of where CAR-T is available in China and what it costs, see our CAR-T treatment guide.
The Patient's Situation Before CAR-T
Patient: referred to in reporting as "Aunt Teng" / Ms. Teng (pseudonym)
Diagnosis: Lymphoma, diagnosed earlier in 2021
Disease course: Initial treatment achieved only partial control; the remaining lesions progressed rapidly despite salvage (rescue) treatment
Complication: Cancer cells had spread throughout her skeleton, causing pathological fractures — bone fractures caused by disease weakening the bone rather than trauma — leaving her in severe pain and unable to walk without a wheelchair
Why standard options ran out: Per the hospital's Phase I Clinical Trial Ward director, even newer targeted therapies were unlikely to help — meeting the clinical definition of refractory disease
"Ms. Teng has refractory lymphoma, and even with newer targeted therapies, it is difficult for her to benefit," the treating professor said.
After multidisciplinary evaluation, the lymphoma treatment team offered CAR-T cell immunotherapy as one of the further treatment options.
The Medical Team & Institution
A top-ranked 3A-grade cancer hospital in Shanghai— one of China's highest-ranked cancer hospitals and a major national referral center for oncology, with a dedicated Phase I Clinical Trial Ward for early-phase cell and drug therapies.
The Director of the Phase I Clinical Trial Ward — a professor overseeing early-phase cell therapy trials at the hospital.
A professor from the Lymphoma Specialty Group — part of the multidisciplinary lymphoma treatment team.
The treating physician on the case — a staff oncologist within the Phase I Clinical Trial Ward.
The Director of the Clinical Research Center — coordinated the multidisciplinary team (MDT) across departments for the case.
According to the treatment team, successful CAR-T therapy depends on extremely strict process management from end to end: collecting the patient's T lymphocytes, expanding and engineering them outside the body so they can recognize tumor antigens, and then reinfusing them under close monitoring.
Treatment Timeline
Stage | What Happened |
Early 2021 | Lymphoma diagnosed; initial treatment achieves only partial control |
Mid-2021 | Salvage treatment given; remaining lesions progress rapidly; disease spreads through skeleton, causing pathological fractures |
Multidisciplinary evaluation | Lymphoma team confirms disease is refractory to further targeted therapy; CAR-T offered as a treatment option |
Early October 2021 | T-cell collection (leukapheresis) completed |
November 2021 | Engineered CAR-T cells reinfused |
Post-infusion | Close inpatient monitoring in the Phase I Clinical Trial Ward; no significant adverse reactions reported |
~1 month post-infusion | All lab indicators normal; PET/CT shows all previously high-uptake lesions resolved |
"The lesions on the PET/CT have all disappeared. Look at the high-uptake lesions that were visible on the previous scans — they've all vanished," the treatment team reported.
The lymphoma specialist on the team was explicit about the limits of what this snapshot shows: "This shows that CAR-T cell immunotherapy is effective for Ms. Teng. Of course, this is only the follow-up situation one month after treatment; Ms. Teng will need continuous follow-up in the future to further observe the treatment effect."
What This Lymphoma Case Reflects About CAR-T Access in China
The treating physician noted that CAR-T cell immunotherapy is currently used clinically mainly for lymphoma patients who have relapsed after first-line treatment and have no remaining second-line options — exactly the profile this patient fit. She emphasized that administering CAR-T requires thorough evaluation by an experienced medical institution, underscoring that this isn't a therapy offered casually or outside of a structured multidisciplinary process.
Beyond this individual case, this hospital's Phase I Clinical Trial Ward has expanded CAR-T and related cell-therapy research well beyond lymphoma — running collaborative trials with pancreatic surgery, gynecologic oncology, head and neck surgery, and bone and soft tissue surgery departments. Extending CAR-T to solid tumors remains one of the hardest open problems in cancer immunotherapy internationally, and the hospital frames this as active, ongoing work rather than a solved problem.
Reading This Case With the Right Caveats
This is a hospital-reported clinical result, and it's a meaningful signal about CAR-T maturity at a top-tier Chinese cancer center. But it should be read for what it is:
One-month follow-up is early. Durable remission in lymphoma is typically assessed over 6–12+ months; the treating team itself flagged this as a snapshot requiring continued monitoring, not a final outcome.
"Refractory lymphoma responding to CAR-T" is a known, replicated effect — CD19-targeted CAR-T products are FDA- and NMPA-approved specifically for relapsed/refractory large B-cell lymphoma because trials have shown meaningful response rates in this population. This case is consistent with that established evidence base, not an outlier claim.
For international patients and families evaluating CAR-T therapy in China, ChinaCureLink helps with hospital selection, eligibility screening, and end-to-end coordination.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
★★★★★ Daniel Wong · Singapore · Aug 2024 · Verified “I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.” |
Frequently Asked Questions
What type of lymphoma was treated in this case?
The original reporting identifies it as refractory lymphoma with bone involvement (skeletal metastasis causing pathological fractures); the specific lymphoma subtype (e.g., diffuse large B-cell lymphoma) is not specified in the source report.
What does "refractory lymphoma" mean?
It means the lymphoma has stopped responding to standard treatments — in this case, first-line therapy, salvage chemotherapy, and newer targeted drugs had all been tried without lasting control.
How long did the CAR-T process take from start to infusion?
In this case, T-cell collection occurred in early October 2021 and reinfusion in November 2021 — roughly a one-month manufacturing and preparation window, which is typical for CAR-T cell therapy globally.
Did the patient have side effects from CAR-T?
The hospital reported no significant adverse reactions during close monitoring in the Phase I Clinical Trial Ward following reinfusion. CAR-T therapy can carry risks such as cytokine release syndrome and neurotoxicity in some patients, which is why treatment requires monitoring at an experienced institution.
Is this hospital only treating blood cancers with CAR-T?
No — while this case involved lymphoma, the hospital's Phase I Clinical Trial Ward is also running CAR-T and related cell-therapy trials for solid tumors in collaboration with pancreatic surgery, gynecologic oncology, head and neck surgery, and bone/soft tissue surgery departments.
Where can I learn more about CAR-T cost and hospital options in China?
References
Yang Jing & Wang Guangzhao, "Fudan University Cancer Hospital Successfully Treats First Patient With Refractory Lymphoma Using CAR-T Therapy", CNR Shanghai / Sina, December 21, 2021 — original source case report. (Note: the original published news report names the specific Shanghai hospital involved; hospital name is intentionally omitted from the body of this article per internal editorial policy.)
Mirror coverage: "CAR-T疗法成功治疗难治性淋巴瘤患者", Sciencenet.cn, December 2021.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — an international medical concierge company headquartered in New York, specialized in securing premium second opinions from top US hospitals and specialists. With over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized as one of the leading patient access services across North America and the Asia-Pacific, bringing the same standard of expert care coordination to every patient we serve.
Disclaimer
This article is for informational purposes only and does not constitute medical or financial advice. Treatment eligibility, protocols, and outcomes vary by individual patient and disease subtype. Please confirm specifics with a qualified oncologist or a ChinaCureLink coordinator before making treatment decisions.
Comments